
    
      The primary object is to estimate the Objective response rate (ORR) based on investigator
      assessment using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 of the TITAN
      regimen in untreated (1st line) and pretreated (2nd line) subjects with International
      Metastatic RCC Database Consortium (IMDC) intermediate and high risk, advanced Renal cell
      carcinoma (RCC) with clear cell component
    
  